During the past decade, Institute of Genetic Medicine International Centre for Life conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Institute of Genetic Medicine International Centre for Life" are "Duchenne Muscular Dystrophy" (2 trials). Many other conditions were trialed in "Institute of Genetic Medicine International Centre for Life" in a lesser frequency.

Most popular intervention types in "Institute of Genetic Medicine International Centre for Life" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Dosing Extension" (1 trials), "PRO045, 0.15 mg/kg/week" (1 trials), "PRO045, 1.0 mg/kg/week" (1 trials), "PRO045, 3.0 mg/kg/week" (1 trials) and "PRO045, 6.0 mg/kg/week" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institute of Genetic Medicine International Centre for Life" are 2 trials for "Male" genders.

Currently, there are NaN active trials in "Institute of Genetic Medicine International Centre for Life". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Institute of Genetic Medicine International Centre for Life, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Institute of Genetic Medicine International Centre for Life, 2 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".